Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver

Trends in Molecular Medicine

Volumn 19, Issue 9, 2013, Pages 522-535

  Musso, Giovanni ^a   Paschetta, Elena ^b   Gambino, Roberto ^b   Cassader, Maurizio ^b   Molinaro, Federica ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FETUIN A; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; LIVER X RECEPTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; SOMATOMEDIN C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ALTERNATIVE RNA SPLICING; ARCUATE NUCLEUS; BONE; BONE MATRIX; BONE TURNOVER; CARTILAGE MATRIX; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE PREDISPOSITION; FATTY LIVER; FIBROGENESIS; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCOSYLATION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; LIVER CELL; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE;

ADIPOSE TISSUE; BONE AND BONES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GENE REGULATORY NETWORKS; HUMANS; LIVER; METABOLIC SYNDROME X; OBESITY;

EID: 84883817588     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.05.006     Document Type: Review

References (141)

1. Kim H.Y., et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif. Tissue Int. 2010, 86:350-358.
2. Jeon Y.K., et al. Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr. J. 2011, 58:87-93.
3. Li M., et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J. Clin. Endocrinol. Metab. 2012, 97:2033-2038.
4. Pirgon O., et al. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin. Endocrinol. (Oxf.) 2011, 75:189-195.
5. Pardee P.E., et al. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment. Pharmacol. Ther. 2012, 35:248-254.
6. Moon S.S., et al. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 2012, 42:423-429.
7. Campos R.M., et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine 2012, 42:146-156.
8. de Paula F.J.A., et al. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 2010, 26:622-630.
9. Confavreux C.B. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 2011, 79(Suppl. 121):S14-S19.
10. Cao D.X., et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J. Gastroenterol. 2012, 18:3923-3930.
11. Gimba E.R., Tilli T.M. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013, 331:11-17.
12. Bertola A., et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009, 58:125-133.
13. Yilmaz Y., et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig. Liver Dis. 2013, 45:58-62.
14. Lima-Cabello E., et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin. Sci. (Lond.) 2011, 120:239-250.
15. Syn W.K., et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012, 61:1323-1329.
16. Chapman J., et al. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS ONE 2010, 5:e13959.
17. Zeyda M., et al. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 2011, 152:2219-2227.
18. Kiefer F.W., et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011, 54:2132-2142.
19. Kiefer F.W., et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010, 59:935-946.
20. Syn W.K., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53:106-115.
21. Chang I.C., et al. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int. 2010, 21:1401-1409.
22. Chiang T.I., et al. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos. Int. 2011, 22:577-585.
23. Kennedy O.D., et al. Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J. Orthop. Res. 2009, 27:303-309.
24. Musso G., et al. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012, 56:933-942.
25. Urtasun R., et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012, 55:594-608.
26. Zhao J., et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
27. Sun B.S., et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008, 48:1834-1842.
28. Weber G.F., et al. Osteopontin is a marker for cancer aggressiveness and patient survival. Br. J. Cancer 2010, 103:861-869.
29. Dong Q.Z., et al. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology 2013, 57:1024-1034.
30. Chen R.X., et al. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via mechanism involving MMP-2 and uPA. Oncol. Rep. 2011, 25:803-808.
31. Chae S., et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int. J. Oncol. 2009, 35:1409-1416.
32. Bhattacharya S.D., et al. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 2010, 148:291-297.
33. Movahed A., et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J. Bone Miner. Metab. 2012, 30:683-691.
34. Ngarmukos C., et al. A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long-term follow-up cohort. Clin. Endocrinol. 2012, 77:42-46.
35. Oosterwerff M.M., et al. Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. Clin. Endocrinol. (Oxf.) 2013, 78:242-247.
36. Bezerra dos Santos Magalhães K., et al. Metabolic syndrome and central fat distribution are related to lower serum osteocalcin concentrations. Ann. Nutr. Metab. 2013, 62:181-186.
37. Iki M., et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int. 2012, 23:761-770.
38. Bao Y., et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J. Clin. Endocrinol. Metab. 2013, 98:345-351.
39. Greco E.A., et al. Negative association between trunk fat, insulin resistance and skeleton in obese women. World J. Diabetes 2013, 4:31-39.
40. Fernández-Real J.M., et al. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int. 2010, 21:2101-2107.
41. Dou J., et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin. Exp. Pharmacol. Physiol. 2013, 40:282-288.
42. Yilmaz Y., et al. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand. J. Clin. Lab. Invest. 2011, 71:631-636.
43. Aller R., et al. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann. Hepatol. 2011, 10:50-55.
44. Ferron M., et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5266-5270.
45. Ferron M., et al. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 2012, 50:568-575.
46. Fulzele K., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
47. Rached M.T., et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J. Clin. Invest. 2010, 120:357-368.
48. Yang S., et al. Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. J. Biol. Chem. 2011, 286:19149-19158.
49. Ferron M., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
50. Kode A., et al. FoxO1 protein cooperates with ATF4 protein in osteoblasts to control glucose homeostasis. J. Biol. Chem. 2012, 287:8757-8768.
51. Zhou B., et al. Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway. Endocrinology 2013, 154:1055-1068.
52. Ducy P., et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382:448-452.
53. Bullò M., et al. Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk. Am. J. Clin. Nutr. 2012, 95:249-255.
54. Pi M., Quarles L.D. Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology 2012, 153:2062-2069.
55. Pi M., et al. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J. Bone Miner. Res. 2011, 26:1680-1683.
56. Mizokami A., et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS ONE 2013, 8:e57375.
57. Mori K., et al. Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2012, 4:53.
58. Abseyi N., et al. Relationships between osteocalcin, glucose metabolism, and adiponectin in obese children: is there crosstalk between bone tissue and glucose metabolism?. J. Clin. Res. Pediatr. Endocrinol. 2012, 4:182-188.
59. Reid P., Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur. J. Cell Biol. 2009, 88:1-17.
60. Schneeweis L.A., et al. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J. Biol. Chem. 2005, 280:41155-41164.
61. Luo X.H., et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J. Bone Miner. Res. 2006, 21:1648-1656.
62. Wang Q.P., et al. Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand. Bone 2012, 51:515-523.
63. Vijayan V., et al. Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: pivotal role of the redox regulator forkhead O1. Free Radic. Biol. Med. 2013, 61C:72-84.
64. Harsløf T., et al. The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture. Horm. Metab. Res. 2011, 43:477-482.
65. Scholtysek C., et al. PPARβ/δ governs Wnt signaling and bone turnover. Nat. Med. 2013, 19:608-613.
66. Kleyer A., et al. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J. Bone Miner. Res. 2012, 27:2442-2451.
67. Musso G., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55:885-904.
68. Musso G., et al. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52:175-191.
69. Beck G.R., et al. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl. Res. 2013, 161:145-155.
70. Stern A., et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor κB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur. J. Endocrinol. 2007, 156:555-562.
71. Mezquita-Raya P., et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005, 16:1368-1374.
72. Ashley D.T., et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011, 60:994-1000.
73. Pepene C.E., et al. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur. J. Endocrinol. 2011, 164:61-68.
74. Nabipour I., et al. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010, 59:742-747.
75. Yilmaz Y., et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand. J. Clin. Lab. Invest. 2010, 70:541-546.
76. McClung M.R., et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006, 354:821-831.
77. Kiechl S., et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 2013, 19:358-363.
78. Mori K., et al. Fetuin-A: a multifunctional protein. Recent Pat. Endocr. Metab. Immune Drug Discov. 2011, 5:124-146.
79. Mathews S.T., et al. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem. Biophys. Res. Commun. 2006, 350:437-443.
80. Hennige A.M., et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 2008, 3:e1765.
81. Siddiq A., et al. A synonymous coding polymorphism in the α2-Heremans-Schmid glycoprotein gene is associated with type-2 diabetes in French Caucasians. Diabetes 2005, 54:2477-2481.
82. Ou H.Y., et al. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin. Endocrinol. (Oxf.) 2011, 75:450-455.
83. Xu Y. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011, 216:180-186.
84. Sun Q., et al. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 2013, 62:49-55.
85. Mori K. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 2008, 57:1248-1252.
86. Stefan N., et al. α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006, 29:853-857.
87. Yilmaz Y., et al. Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann. Clin. Biochem. 2010, 47:549-553.
88. Kahraman A., et al. Fetuin-A mRNA expression is elevated in NASH compared to NAFL patients. Clin. Sci. (Lond.) 2013, 10.1042/CS20120542.
89. Haukeland J.W. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur. J. Endocrinol. 2012, 166:503-510.
90. Ou H.Y., et al. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 2012, 153:2974-2984.
91. Pal D., et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 2012, 10.1038/nm.2851.
92. Jahnen-Dechent W., et al. Fetuin-A regulation of calcified matrix metabolism. Circ. Res. 2011, 108:1494-1509.
93. Herrmann M., et al. Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc. Med. 2012, 22:197-201.
94. Herrmann M., et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ. Res. 2012, 111:575-584.
95. Price P.A., et al. Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. J. Biol. Chem. 2009, 284:17092-17101.
96. Toroian D., Price P.A. The essential role of fetuin in the serum-induced calcification of collagen. Calcif. Tissue Int. 2008, 82:116-126.
97. Binkert C., et al. Regulation of osteogenesis by fetuin. J. Biol. Chem. 1999, 274:28514-28520.
98. Seto J., et al. Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-A knockout mice. PLoS ONE 2012, 7:e47338.
99. Ix J.H., et al. Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) Study. J. Bone Miner. Res. 2009, 24:514-521.
100. Rasul S. Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin. Endocrinol. (Oxf.) 2012, 76:499-505.
101. Amitani M., et al. The role of leptin in the control of insulin-glucose axis. Front. Neurosci. 2013, 7:51.
102. Miyamoto L., et al. Leptin activates hepatic 5'AMP-activated protein kinase through sympathetic nervous system and α1 adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin. J. Biol. Chem. 2012, 287:40441-40447.
103. Huynh F.K., et al. A role for hepatic leptin signaling in lipid metabolism via altered very low density lipoprotein composition and liver lipase activity in mice. Hepatology 2013, 57:543-554.
104. Minokoshi Y., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
105. Ebihara K., et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 2007, 92:532-541.
106. Lee J.H., et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 2006, 91:2605-2611.
107. Machado M.V., et al. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2012, 24:1166-1172.
108. Kalra S.P., et al. Pivotal role of leptin-hypothalamus signalling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention?. Gene Ther. 2011, 18:319-325.
109. St-Pierre J., Tremblay M.L. Modulation of leptin resistance by protein tyrosine phosphatases. Cell Metab. 2012, 15:292-297.
110. Imajo K., et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012, 16:44-54.
111. Zhang W., et al. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. Int. J. Biochem. Cell Biol. 2013, 45:736-744.
112. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
113. Yadav V.K., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
114. Ducy P., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
115. Takeda S., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
116. Zeadin M.G., et al. Leptin promotes osteoblast differentiation and mineralization of primary cultures of vascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3β. Biochem. Biophys. Res. Commun. 2012, 425:924-930.
117. Hedbacker K., et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010, 11:11-22.
118. DeMambro V.E., et al. Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J. Bone Miner. Res. 2012, 27:390-400.
119. Tsuji K., et al. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1α,25-dihydroxyvitamin D3 synthesis in leptin-deficient ob/ob mice. J. Bone Miner. Res. 2010, 25:1711-1723.
120. Morcov C., et al. Correlation between adiponectin, leptin, insulin growth factor-1 and bone mineral density in pre and postmenopausal women. Rev. Med. Chir. Soc. Med. Nat. Iasi 2012, 116:785-789.
121. Campos R.M., et al. Interaction of bone mineral density, adipokines and hormones in obese adolescents girls submitted in an interdisciplinary therapy. J. Pediatr. Endocrinol. Metab. 2013, 22:1-6.
122. Gambino R., et al. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2011, 15:1325-1365.
123. Federico A., et al. Fat: a matter of disturbance for the immune system. World J. Gastroenterol. 2010, 16:4762-4772.
124. Koca S.S., et al. The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008, 31:91-98.
125. Alaaeddine N., et al. TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. Eur. Cytokine Netw. 2012, 23:107-111.
126. Zou W., et al. Tumor necrosis factor-α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J. Cell. Biochem. 2001, 83:70-83.
127. Kawai V.K. Effects of anti-tumor necrosis factor α agents on bone. Curr. Opin. Rheumatol. 2012, 24:576-585.
128. Lee H.L., et al. Msx2 mediates the inhibitory action of TNF-α on osteoblast differentiation. Exp. Mol. Med. 2010, 42:437-445.
129. Ochi H., et al. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. J. Orthop. Res 2010, 28:657-663.
130. Nanes M.S. Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 2003, 321:1-15.
131. Calton E.K., et al. Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin?. Eur. J. Clin. Nutr. 2013, 67:485-491.
132. Musso G., et al. Emerging molecular targets for the treatment of non-alcoholic fatty liver disease. Annu. Rev. Med. 2010, 61:375-392.
133. Xu A., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112:91-100.
134. Williams G.A., et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology 2009, 150:3603-3610.
135. Tu Q., et al. Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J. Biol. Chem. 2011, 286:12542-12553.
136. Biver E., et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2011, 96:2703-2713.
137. Pluskiewicz W., et al. Adiponectin and resistin in relationship with skeletal status in women from the RAC-OST-POL study. Endokrynol. Pol. 2012, 63:427-431.
138. Johansson H., et al. High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J. Bone Miner. Res. 2012, 27:1390-1396.
139. Kanazawa I., et al. Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. Metabolism 2010, 59:1252-1256.
140. Tenta R., et al. Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J. Endocrinol. Invest. 2012, 35:306-311.
141. Schafer A.L., et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). Clin. Endocrinol. Metab. 2011, 96:E1982-E1989.